LXXLL peptide converts transportan 10 to a potent inducer of apoptosis in breast cancer cells

International Journal of Molecular Sciences

Volumn 15, Issue 4, 2014, Pages 5680-5698

  Tints, Kairit ^a   Prink, Madis ^a,b   Neuman, Toomas ^a   Palm, Kaia ^a,c  

^a Protobios LLC   (Estonia)

^b Department of Immunotherapy   (Estonia)

^c TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

Author keywords

Cancer; Cell penetrating peptide; LXXLL; SRC 1

Indexed keywords

7 AMINODACTINOMYCIN; APOPTOSIS INDUCING FACTOR; CATHEPSIN D; CELL NUCLEUS RECEPTOR; CELL PENETRATING PEPTIDE; ESTROGEN RECEPTOR ALPHA; LIPOCORTIN 5; POLYARGININE; PROTEIN BCL 2; PROTEIN PS2; STEROID RECEPTOR COACTIVATOR 1; TRANSPORTAN 10; UNCLASSIFIED DRUG; CDK5RAP3 PROTEIN, HUMAN; ESTROGEN RECEPTOR BETA; HYBRID PROTEIN; NCOA1 PROTEIN, HUMAN; NERVE PROTEIN; PROTEIN BINDING; SIGNAL PEPTIDE; TFF1 PROTEIN, HUMAN; TRANSPORTAN-10; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL VIABILITY; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FIBROBLAST CULTURE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LXXLL MOTIF; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MRNA EXPRESSION ASSAY; NUCLEAR LOCALIZATION SIGNAL; PROTEIN MOTIF; PROTEIN PURIFICATION; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; WST-1 ASSAY; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

AMINO ACID MOTIFS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MCF-7 CELLS; NERVE TISSUE PROTEINS; NUCLEAR RECEPTOR COACTIVATOR 1; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84898727051     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15045680     Document Type: Article

References (77)

1. Mohla, S.; Stearns, V.; Sathyamoorthy, N.; Rosenfeld, M. G.; Nelson, P. The biology of hormone refractory breast and prostate cancer: An NCI workshop report. Cancer Biol. Ther. 2009, 8, 1975-1985.
2. Chang, C.; Norris, J. D.; Gron, H.; Paige, L. A.; Hamilton, P. T.; Kenan, D. J.; Fowlkes, D.; McDonnell, D. P. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: Discovery of peptide antagonists of estrogen receptors alpha and beta. Mol. Cell. Biol. 1999, 19, 8226-8239.
3. Heery, D. M.; Hoare, S.; Hussain, S.; Parker, M. G.; Sheppard, H. Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J. Biol. Chem. 2001, 276, 6695-6702.
4. McInerney, E. M.; Rose, D. W.; Flynn, S. E.; Westin, S.; Mullen, T. M.; Krones, A.; Inostroza, J.; Torchia, J.; Nolte, R. T.; Assa-Munt, N.; et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev. 1998, 12, 3357-3368.
5. York, B.; O'Malley, B. W. Steroid receptor coactivator (SRC) family: masters of systems biology. J. Biol. Chem. 2010, 285, 38743-38750.
6. Hong, H.; Kohli, K.; Trivedi, A.; Johnson, D. L.; Stallcup, M. R. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. USA 1996, 93, 4948-4952.
7. Torchia, J.; Rose, D. W.; Inostroza, J.; Kamei, Y.; Westin, S.; Glass, C. K.; Rosenfeld, M. G. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 1997, 387, 677-684.
8. Onate, S. A.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270, 1354-1357.
9. Heery, D. M.; Kalkhoven, E.; Hoare, S.; Parker, M. G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997, 387, 733-736.
10. Parker, D.; Rivera, M.; Zor, T.; Henrion-Caude, A.; Radhakrishnan, I.; Kumar, A.; Shapiro, L. H.; Wright, P. E.; Montminy, M.; Brindle, P. K. Role of secondary structure in discrimination between constitutive and inducible activators. Mol. Cell. Biol. 1999, 19, 5601-5607.
11. Litterst, C. M.; Pfitzner, E. An LXXLL motif in the transactivation domain of STAT6 mediates recruitment of NCoA-1/SRC-1. J. Biol. Chem. 2002, 277, 36052-36060.
12. Lee, J. E.; Kim, K.; Sacchettini, J. C.; Smith, C. V.; Safe, S. DRIP150 coactivation of estrogen receptor alpha in ZR-75 breast cancer cells is independent of LXXLL motifs. J. Biol. Chem. 2005, 280, 8819-8830.
13. Zhang, J.; Fondell, J. D. Identification of mouse TRAP100: A transcriptional coregulatory factor for thyroid hormone and vitamin D receptors. Mol. Endocrinol. 1999, 13, 1130-1140.
14. Wang, J. C.; Stafford, J. M.; Granner, D. K. SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4. J. Biol. Chem. 1998, 273, 30847-30850.
15. Zhu, Y.; Qi, C.; Calandra, C.; Rao, M. S.; Reddy, J. K. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr. 1996, 6, 185-195.
16. Ding, X. F.; Anderson, C. M.; Ma, H.; Hong, H.; Uht, R. M.; Kushner, P. J.; Stallcup, M. R. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): Multiple motifs with different binding specificities. Mol. Endocrinol. 1998, 12, 302-313.
17. Zhou, G.; Cummings, R.; Li, Y.; Mitra, S.; Wilkinson, H. A.; Elbrecht, A.; Hermes, J. D.; Schaeffer, J. M.; Smith, R. G.; Moller, D. E. Nuclear receptors have distinct affinities for coactivators: Characterization by fluorescence resonance energy transfer. Mol. Endocrinol. 1998, 12, 1594-1604.
18. Lee, S. K.; Kim, H. J.; Na, S. Y.; Kim, T. S.; Choi, H. S.; Im, S. Y.; Lee, J. W. Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J. Biol. Chem. 1998, 273, 16651-16654.
19. Kim, H. J.; Kim, J. H.; Lee, J. W. Steroid receptor coactivator-1 interacts with serum response factor and coactivates serum response element-mediated transactivations. J. Biol. Chem. 1998, 273, 28564-28567.
20. Na, S. Y.; Lee, S. K.; Han, S. J.; Choi, H. S.; Im, S. Y.; Lee, J. W. Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations. J. Biol. Chem. 1998, 273, 10831-10834.
21. Myers, E.; Hill, A. D.; Kelly, G.; McDermott, E. W.; O'Higgins, N. J.; Buggy, Y.; Young, L. S. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin. Cancer Res. 2005, 11, 2111-2122.
22. McIlroy, M.; McCartan, D.; Early, S.; Gaora, P. O.; Pennington, S.; Hill, A. D.; Young, L. S. Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer. Cancer Res. 2010, 70, 1585-1594.
23. Qin, L.; Chen, X.; Wu, Y.; Feng, Z.; He, T.; Wang, L.; Liao, L.; Xu, J. Steroid receptor coactivator-1 upregulates integrin alpha(5) expression to promote breast cancer cell adhesion and migration. Cancer Res. 2011, 71, 1742-1751.
24. Xu, J.; Wu, R. C.; O'Malley, B. W. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat. Rev. Cancer 2009, 9, 615-630.
25. Puigserver, P.; Adelmant, G.; Wu, Z.; Fan, M.; Xu, J.; O'Malley, B.; Spiegelman, B. M. Activation of PPARgamma coactivator-1 through transcription factor docking. Science 1999, 286, 1368-1371.
26. Picard, F.; Gehin, M.; Annicotte, J.; Rocchi, S.; Champy, M. F.; O'Malley, B. W.; Chambon, P.; Auwerx, J. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 2002, 111, 931-941.
27. Chopra, A. R.; Louet, J. F.; Saha, P.; An, J.; Demayo, F.; Xu, J.; York, B.; Karpen, S.; Finegold, M.; Moore, D.; et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling von Gierke's disease. Science 2008, 322, 1395-1399.
28. Redmond, A. M.; Bane, F. T.; Stafford, A. T.; McIlroy, M.; Dillon, M. F.; Crotty, T. B.; Hill, A. D.; Young, L. S. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin. Cancer Res. 2009, 15, 2098-2106.
29. Fleming, F. J.; Myers, E.; Kelly, G.; Crotty, T. B.; McDermott, E. W.; O'Higgins, N. J.; Hill, A. D.; Young, L. S. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J. Clin. Pathol. 2004, 57, 1069-1074.
30. Hudelist, G.; Czerwenka, K.; Kubista, E.; Marton, E.; Pischinger, K.; Singer, C. F. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res. Treat. 2003, 78, 193-204.
31. Agoulnik, I. U.; Vaid, A.; Bingman, W. E., 3rd; Erdeme, H.; Frolov, A.; Smith, C. L.; Ayala, G.; Ittmann, M. M.; Weigel, N. L. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005, 65, 7959-7967.
32. Tai, H.; Kubota, N.; Kato, S. Involvement of nuclear receptor coactivator SRC-1 in estrogen-dependent cell growth of MCF-7 cells. Biochem. Biophys. Res. Commun. 2000, 267, 311-316.
33. Gehin, M.; Mark, M.; Dennefeld, C.; Dierich, A.; Gronemeyer, H.; Chambon, P. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol. Cell. Biol. 2002, 22, 5923-5937.
34. Xu, J.; Liao, L.; Ning, G.; Yoshida-Komiya, H.; Deng, C.; O'Malley, B. W. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc. Natl. Acad. Sci. USA 2000, 97, 6379-6384.
35. Wang, Z.; Rose, D. W.; Hermanson, O.; Liu, F.; Herman, T.; Wu, W.; Szeto, D.; Gleiberman, A.; Krones, A.; Pratt, K.; et al. Regulation of somatic growth by the p160 coactivator p/CIP. Proc. Natl. Acad. Sci. USA 2000, 97, 13549-13554.
36. Savkur, R. S.; Burris, T. P. The coactivator LXXLL nuclear receptor recognition motif. J. Pept. Res. 2004, 63, 207-212.
37. Norris, J. D.; Paige, L. A.; Christensen, D. J.; Chang, C. Y.; Huacani, M. R.; Fan, D.; Hamilton, P. T.; Fowlkes, D. M.; McDonnell, D. P. Peptide antagonists of the human estrogen receptor. Science 1999, 285, 744-746.
38. Leduc, A. M.; Trent, J. O.; Wittliff, J. L.; Bramlett, K. S.; Briggs, S. L.; Chirgadze, N. Y.; Wang, Y.; Burris, T. P.; Spatola, A. F. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc. Natl. Acad. Sci. USA 2003, 100, 11273-11278.
39. Geistlinger, T. R.; Guy, R. K. Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J. Am. Chem. Soc. 2003, 125, 6852-6853.
40. Rodriguez, A. L.; Tamrazi, A.; Collins, M. L.; Katzenellenbogen, J. A. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor α coactivator binding. J. Med. Chem. 2004, 47, 600-611.
41. Zhou, H. B.; Collins, M. L.; Gunther, J. R.; Comninos, J. S.; Katzenellenbogen, J. A. Bicyclo [2. 2. 2] octanes: Close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators. Bioorg. Med. Chem. Lett. 2007, 17, 4118-4122.
42. LaFrate, A. L.; Gunther, J. R.; Carlson, K. E.; Katzenellenbogen, J. A. Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor. Bioorg. Med. Chem. Lett. 2008, 16, 10075-10084.
43. Parent, A. A.; Gunther, J. R.; Katzenellenbogen, J. A. Blocking estrogen signaling after the hormone: Pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J. Med. Chem. 2008, 51, 6512-6530.
44. Gunther, J. R.; Moore, T. W.; Collins, M. L.; Katzenellenbogen, J. A. Amphipathic benzenes are designed inhibitors of the estrogen receptor alpha/steroid receptor coactivator interaction. ACS Chem. Biol. 2008, 3, 282-286.
45. Gunther, J. R.; Parent, A. A.; Katzenellenbogen, J. A. Alternative inhibition of androgen receptor signaling: Peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem. Biol. 2009, 4, 435-440.
46. Howl, J.; Matou-Nasri, S.; West, D. C.; Farquhar, M.; Slaninova, J.; Ostenson, C. G.; Zorko, M.; Ostlund, P.; Kumar, S.; Langel, U.; et al. Bioportide: An emergent concept of bioactive cell-penetrating peptides. Cell. Mol. Life Sci. 2012, 69, 2951-2966.
47. El-Andaloussi, S.; Holm, T.; Langel, U. Cell-penetrating peptides: Mechanisms and applications. Curr. Pharm. Des. 2005, 11, 3597-3611.
48. Portoghese, P. S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 1989, 10, 230-235.
49. Soomets, U.; Lindgren, M.; Gallet, X.; Hallbrink, M.; Elmquist, A.; Balaspiri, L.; Zorko, M.; Pooga, M.; Brasseur, R.; Langel, U. Deletion analogues of transportan. Biochim. Biophys. Acta 2000, 1467, 165-176.
50. Bramlett, K. S.; Wu, Y.; Burris, T. P. Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol. Endocrinol. 2001, 15, 909-922.
51. Futaki, S. Oligoarginine vectors for intracellular delivery: Design and cellular-uptake mechanisms. Biopolymers 2006, 84, 241-249.
52. Jones, S. W.; Christison, R.; Bundell, K.; Voyce, C. J.; Brockbank, S. M.; Newham, P.; Lindsay, M. A. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br. J. Pharmacol. 2005, 145, 1093-1102.
53. Madani, F.; Lindberg, S.; Langel, U.; Futaki, S.; Graslund, A. Mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys. 2011, 2011, 414729: 1-414729: 1.
54. Verdurmen, W. P.; Brock, R. Biological responses towards cationic peptides and drug carriers. Trends Pharmacol. Sci. 2011, 32, 116-124.
55. Saar, K.; Lindgren, M.; Hansen, M.; Eiriksdottir, E.; Jiang, Y.; Rosenthal-Aizman, K.; Sassian, M.; Langel, U. Cell-penetrating peptides: A comparative membrane toxicity study. Anal. Biochem. 2005, 345, 55-65.
56. Jones, S.; Holm, T.; Mager, I.; Langel, U.; Howl, J. Characterization of bioactive cell penetrating peptides from human cytochrome c: Protein mimicry and the development of a novel apoptogenic agent. Chem. Biol. 2010, 17, 735-744.
57. Ward, B.; Seal, B. L.; Brophy, C. M.; Panitch, A. Design of a bioactive cell-penetrating peptide: When a transduction domain does more than transduce. J. Pept. Sci. 2009, 15, 668-674.
58. Hoskin, D. W.; Ramamoorthy, A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta 2008, 1778, 357-375.
59. Zhao, J.; Gao, P.; Xiao, W.; Fan, L. Q.; Wang, F. J.; Li, S. X.; Liu, J. W. A novel human derived cell-penetrating peptide in drug delivery. Mol. Biol. Rep. 2011, 38, 2649-2656.
60. Panno, M. L.; Salerno, M.; Pezzi, V.; Sisci, D.; Maggiolini, M.; Mauro, L.; Morrone, E. G.; Ando, S. Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells. J. Cancer Res. Clin. Oncol. 1996, 122, 745-749.
61. Roodi, N.; Bailey, L. R.; Kao, W. Y.; Verrier, C. S.; Yee, C. J.; Dupont, W. D.; Parl, F. F. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst. 1995, 87, 446-451.
62. Ottaviano, Y. L.; Issa, J. P.; Parl, F. F.; Smith, H. S.; Baylin, S. B.; Davidson, N. E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994, 54, 2552-2555.
63. Quong, M. W.; Romanow, W. J.; Murre, C. E protein function in lymphocyte development. Annu. Rev. Immunol. 2002, 20, 301-322.
64. Massari, M. E.; Murre, C. Helix-loop-helix proteins: Regulators of transcription in eucaryotic organisms. Mol. Cell. Biol. 2000, 20, 429-440.
65. Lassar, A. B.; Davis, R. L.; Wright, W. E.; Kadesch, T.; Murre, C.; Voronova, A.; Baltimore, D.; Weintraub, H. Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 1991, 66, 305-315.
66. Murre, C. Role of helix-loop-helix proteins in lymphocyte development. Cold Spring Harb. Symp. Quant. Biol. 1999, 64, 39-44.
67. Pagliuca, A.; Gallo, P.; de Luca, P.; Lania, L. Class A helix-loop-helix proteins are positive regulators of several cyclin-dependent kinase inhibitors' promoter activity and negatively affect cell growth. Cancer Res. 2000, 60, 1376-1382.
68. Zhang, Z.; Gu, J.; Gu, X. How much expression divergence after yeast gene duplication could be explained by regulatory motif evolution? Trends Genet. 2004, 20, 403-407.
69. Torchia, J.; Glass, C.; Rosenfeld, M. G. Co-activators and co-repressors in the integration of transcriptional responses. Curr. Opin. Cell Biol. 1998, 10, 373-383.
70. Jiang, P.; Hu, Q.; Ito, M.; Meyer, S.; Waltz, S.; Khan, S.; Roeder, R. G.; Zhang, X. Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation. Proc. Natl. Acad. Sci. USA 2010, 107, 6765-6770.
71. Bersten, D. C.; Sullivan, A. E.; Peet, D. J.; Whitelaw, M. L. bHLH-PAS proteins in cancer. Nat. Rev. Cancer 2013, 13, 827-841.
72. Karmakar, S.; Foster, E. A.; Smith, C. L. Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Endocrinology 2009, 150, 1588-1596.
73. Watkins, C. L.; Sayers, E. J.; Allender, C.; Barrow, D.; Fegan, C.; Brennan, P.; Jones, A. T. Co-operative membrane disruption between cell-penetrating peptide and cargo: Implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8. Mol. Ther. 2011, 19, 2124-2132.
74. Kurebayashi, S.; Nakajima, T.; Kim, S. C.; Chang, C. Y.; McDonnell, D. P.; Renaud, J. P.; Jetten, A. M. Selective LXXLL peptides antagonize transcriptional activation by the retinoid-related orphan receptor RORgamma. Biochem. Biophys. Res. Commun. 2004, 315, 919-927.
75. Mettu, N. B.; Stanley, T. B.; Dwyer, M. A.; Jansen, M. S.; Allen, J. E.; Hall, J. M.; McDonnell, D. P. The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. Mol. Endocrinol. 2007, 21, 2361-2377.
76. Bhoumik, A.; Huang, T. G.; Ivanov, V.; Gangi, L.; Qiao, R. F.; Woo, S. L.; Chen, S. H.; Ronai, Z. An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J. Clin. Investig. 2002, 110, 643-650.
77. Montigiani, S.; Muller, R.; Kontermann, R. E. Inhibition of cell proliferation and induction of apoptosis by novel tetravalent peptides inhibiting DNA binding of E2F. Oncogene 2003, 22, 4943-4952.